JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $177 from $179 and keeps an Overweight rating on the shares after meeting with management. The firm sees potential upside to Crenessity estimates in Q4 and 2026. For Ingrezza, it sees Q4 sales more in-line with guidance.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $169 from $172 at Truist
- Neurocrine downgraded to Equal Weight from Overweight at Morgan Stanley
- RBC Capital would be a buyer of Neurocrine on weakness following competitor data
- Neurocrine Biosciences: Ingrezza-Driven Strength and Risk-Balanced Pipeline Support Buy Rating Despite Valbenazine Setback
- Buy Rating Reaffirmed on Neurocrine: Limited Impact from Trial Setback, Strength in Core Execution and Deep Pipeline Upside